Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.92 USD | +2.14% | -3.97% | -22.35% |
05-09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
05-08 | Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.35% | 1.15B | |
+23.00% | 44.96B | |
+1.07% | 42.65B | |
+45.83% | 41.85B | |
-5.31% | 29.04B | |
+11.09% | 26.08B | |
-21.37% | 19.03B | |
+6.38% | 12.75B | |
+28.63% | 12.06B | |
-3.87% | 11.75B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Morgan Stanley Lowers Pharvaris to Equalweight From Overweight, Price Target to $10 From $40